Melanoma is one of the most common primary tumours associated with metastatic spinal cord compression (MSCC). The aim of this review is to identify prognostic factors specifically for MSCC secondary to melanoma. A systematic search of literature was performed in MEDLINE, Embase and the Cochrane Library to identify studies reporting prognostic factors for patients with MSCC secondary to melanoma. Two studies, involving a total of 39 patients, fulfilled the inclusion criteria. The variables associated with increased survival were receiving postoperative radiotherapy, receiving chemotherapy, perioperative lactate dehydrogenase level less than or equal to 8.0 µkat/l, preoperative haemoglobin level more than 11.5 mg/dl, an interval of 4 or more years between melanoma diagnosis and skeletal metastasis, absence of further skeletal metastases, absence of visceral metastases, Eastern Cooperative Oncology Group Performance Status of 2 or less, two or fewer involved vertebrae, being ambulatory preradiotherapy and an interval of more than 7 days between developing motor deficits and radiotherapy. The variables associated with good functional outcome were slow development of motor dysfunction, good performance status and being ambulatory before radiotherapy. The most important prognostic factors for survival are Eastern Cooperative Oncology Group Performance Status of 2 or less and absence of visceral metastases. There is a lack of studies looking specifically at prognostic factors for patients with MSCC secondary to melanoma, and the number of patients involved in the existing studies is small. Melanoma Res 28:1-7 Copyright
Introduction
Melanoma is the fifth most common cancer in the UK, with an incidence of around 13 000 cases per year [1] . Metastatic spinal cord compression (MSCC) affects 5-10% of cancer patients. The most common primary tumours associated with MSCC are lung, breast, prostate, gastrointestinal and kidney cancers and melanoma [2] . Overall, 60% of patients with disseminated malignant melanoma will develop skeletal metastases [3] . This can have a severely negative effect on quality of life for these patients, causing pain, compression fractures and MSCC [4] .
The treatment for MSCC is decided on an individual patient basis and may include corticosteroids, radiotherapy and/or decompressive surgery [2] . Despite these therapies, survival rates are low, with most patients having a life span of less than 6 months [3, 5, 6] . NICE guidance stipulates that surgery should only be offered to patients with a life expectancy of 3 months or greater [7] . However, melanoma is considered to be a relatively radioresistant tumour, suggesting that melanoma patients may derive greater benefit from surgical decompression than those with more radiosensitive primary tumours [8, 9] . It would therefore seem desirable to be able to identify melanoma patients expected to survive for at least 3 months before treatment commences.
A recent systematic review identified prognostic factors for patients with MSCC secondary to lung cancer [10] . A number of studies describe prognostic factors for MSCC secondary to cancer of unknown primary [11] , relatively radioresistant tumours (renal cell carcinoma, colorectal cancer and melanoma) [8] and a variety of primary tumours [12, 13] . However, no reviews have been published examining the prognostic factors for patients with MSCC secondary to melanoma.
Variables found to be significant for survival on multivariate analysis in previous studies include female sex [10] , Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or less [8, 10, 11] , being ambulatory preradiotherapy [10] [11] [12] , being ambulatory postoperatively [10] , absence of further skeletal metastases [10, 12] , absence of visceral metastases [10] [11] [12] , an interval of more than 15 months between cancer diagnosis and MSCC [10, 12] , an interval of more than 7 days between developing motor deficits and radiotherapy [8, [10] [11] [12] , an improvement in neurological status [10] , involvement of fewer than three vertebrae [13] and favourable histology [12] .
The only variable found to be significant for functional outcome on multivariate analysis in these studies was an interval of more than 15 months between cancer diagnosis and MSCC [8] . Variables found to be significant for local control on multivariate analysis in these studies included absence of visceral metastases and long-course radiotherapy [12] .
The aim of this paper is to identify predictive prognostic factors affecting survival, functional outcome and local control for patients with MSCC secondary to melanoma to aid the planning of therapy.
Patients and methods
This systematic review was performed following the PRISMA statement [14] . The review protocol can be found in the PROSPERO prospective register of systematic reviews [15] . Indexed studies were identified in MEDLINE, Embase and the Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials and Cochrane Methodology Register) using the following search terms: spinal cord compression; metastatic spinal cord compression; melanoma; and malignant melanoma. The search strategy can be found online [15] .
Included studies described prognostic factors for patients presenting with MSCC secondary to melanoma. Studies that did not address prognostic factors for melanoma patients specifically were excluded.
The database search and screening of study titles was performed by one reviewer (N.H.). Abstracts and, when necessary, the full text of the remaining studies were assessed for eligibility by two reviewers (N.H. and J.M.). Cases of disagreement were resolved through discussion moderated by a third reviewer (P.W.). The reference lists of selected articles were checked for other articles that fulfilled the inclusion criteria.
The data in each of the eligible studies were extracted by two reviewers (N.H. and P.W.) using a predetermined form, which included the year the study was published; the country of origin of the study; the type of study; the number of participants, and the number of these with MSCC; the criteria for the patients to be included in the study; the prognostic factors investigated by the study; the significance of the factors on a given outcome; and any further information considered to be relevant, including patient demographics (age and sex). Missing data were requested as necessary from the corresponding author.
The quality of each of the included studies was assessed using the Good Research for Comparative Effectiveness (GRACE) checklist developed by Dreyer et al. [16] for observational studies. Two reviewers (N.H. and S.J.) independently assessed the studies according to the checklist items. Cases of disagreement were resolved through discussion moderated by and with input from a third reviewer (P.W.).
The primary summary measures included risk ratio and differences in median value. Quantitative synthesis was not considered to be appropriate for these data. No additional analyses were carried out. Figure 1 shows the process by which studies were selected. Initial database searches of MEDLINE, Embase and the Cochrane Library identified 106 papers. Overall, 19 of these were identified as duplicates and excluded at this stage. The titles and abstracts of the remaining 87 papers were screened for eligibility, excluding 73 of these. Full text of the remaining 14 papers was retrieved and assessed for eligibility, with 12 of these being excluded. No additional eligible papers were identified by manual searching of references lists. Therefore, this systematic review looks at two papers that fulfilled the eligibility criteria.
Results
The GRACE checklist summary is presented in Table 1 . Both studies were considered to be of moderate to high quality as they scored 'sufficient' on all except one of the applicable items.
Data related to the characteristics of the patients involved in the studies are described in Table 2 . In total, 39 patients with MSCC secondary to melanoma were included. Both studies were retrospective cohorts in European settings [3, 5] . The median age was similar between studies and both studies had a preponderance of males [3, 5] . Wedin et al. [3] looked at patients with malignant melanoma whose skeletal metastases were treated surgically; not all of these metastases were vertebral. Huttenlocher et al. [5] looked at patients with a diagnosis of MSCC confirmed by spinal computed tomography or MRI, motor deficit of the legs and no previous radiotherapy or surgery to the affected section of the spinal cord.
The prognostic factors associated with survival are shown in Table 3 . The variables associated with increased survival were receiving postoperative radiotherapy [3] , receiving chemotherapy [3] , perioperative lactate dehydrogenase level less than or equal to 8.0 µkat/l [3], preoperative haemoglobin level more than 11.5 mg/dl [3] , an interval of 4 or more years between melanoma diagnosis and skeletal metastasis [3] , absence of further skeletal metastases [3, 5] , absence of visceral metastases [3, 5] , ECOG Performance Status of 2 or less [5] , two or fewer involved vertebrae [5] , being ambulatory preradiotherapy [5] and an interval of more than 7 days between developing motor deficits and radiotherapy [5] . Wedin et al. [3] also found that vertebral metastases were associated with worse prognosis than other skeletal metastases. Huttenlocher et al. [5] carried out a multivariate analysis using the Cox regression model; absence of visceral metastases and ECOG Performance Status of less than 2 remained significant prognostic factors. Process by which eligible papers were identified. Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
Huttenlocher et al. [5] also looked at prognostic factors associated with postoperative ambulatory status and improvement in motor function. Factors shown to improve postoperative ambulatory status on univariate analysis using the χ 2 -test were ECOG Performance Status of 2 or less (P = 0.046) and being ambulatory before radiotherapy (P < 0.001), with an interval of more than 7 days between developing motor deficits and radiotherapy showing a strong trend (P = 0.051) [5] . The only factor shown to improve motor function on multivariate analysis using the ordered logit model was an interval of more than 7 days between developing motor deficits and radiotherapy (P = 0.006) [5] . Neither paper looked at prognostic factors associated with local control [3, 5] . The corresponding study author was contacted to confirm this. In Wedin et al. [3] , the authors consider primary site of melanoma, but do not state which is investigated as the positive prognostic factor. The corresponding study author was contacted to clarify this. c In Wedin et al. [3] , the authors describe some factors as favourable without mentioning which statistical analyses were carried out to reach this conclusion. The corresponding study author was contacted to clarify this. In Huttenlocher et al. [5] , the authors consider sex, but do not state which is investigated as the positive prognostic factor. The corresponding study author was contacted to clarify this.
Discussion
The most important prognostic factors for survival identified by this review were ECOG Performance Status of 2 or less and absence of visceral metastases. The most important prognostic factors for functional outcome identified by this review were an interval of more than 7 days between developing motor deficits and radiotherapy, ECOG Performance Status of 2 or less and being ambulatory before radiotherapy. No prognostic factors for local control were identified by this review.
To our knowledge, this is the first paper to systematically review the prognostic factors in patients with MSCC secondary to melanoma. The variables found to be significant for survival in this review are consistent with those identified in studies of patients with MSCC secondary to other primary tumours, specifically ECOG Performance Status of 2 or less [8, 10, 11] , being ambulatory preradiotherapy [10] [11] [12] , absence of further skeletal metastases [10, 12] , absence of visceral metastases [10] [11] [12] , a longer interval between cancer diagnosis and MSCC [10, 12] , an interval of more than 7 days between developing motor deficits and radiotherapy [8, [10] [11] [12] and involvement of two or fewer vertebrae [13] .
The number of studies retrieved for this review was small, highlighting that few studies focus specifically on this population. This may be partly explained by the fact that many previous studies have reviewed MSCC caused by all types of tumours. It may also be partly explained by the fact that melanoma is a less common cause of MSCC compared with lung cancer, which Mak et al. [17] showed to be the most common cause.
One included study looked at prognostic factors in patients treated surgically [3] whereas the other looked at patients receiving radiotherapy [5] . This may have influenced the results obtained by the authors as surgery is only offered to those expected to live at least 3 months [7] . However, survival at 6 and 12 months was lower in the surgery group (19 and 13%, respectively) [3] than the radiotherapy group (33 and 22%, respectively) [5] . Furthermore, the median survival in the surgery group was 1.9 months, with a 3-month survival rate of 39%, suggesting that some of these patients should not have been candidates for surgery [5] . The difficulty of identifying patients appropriate for surgery is also highlighted in Divecha et al. [18] , where the probability of survival at 3 months was 66% for their patients (against an expected 100%).
Of the nine factors that were investigated only in Wedin et al. [3] , the significant variables for survival were administration of postoperative radiotherapy, administration of chemotherapy, perioperative lactate dehydrogenase level less than or equal to 8.0 µkat/l and preoperative haemoglobin level more than 11.5 mg/dl. Site of skeletal metastasis was also investigated and it was found that vertebral metastases were associated with worse prognosis than other skeletal metastases, having a median survival of 1.5 months compared with 1.9 months [3] .
However, this prognostic factor is not relevant to this review as it is for MSCC patients. Multivariate analysis was not carried out.
Of the seven factors that were investigated only in Huttenlocher et al. [5] , the significant variables for survival were ECOG Performance Status of 2 or less, two or fewer involved vertebrae, being ambulatory preradiotherapy and an interval of more than 7 days between developing motor deficits and radiotherapy. ECOG Performance Status of 2 or less remained significant on multivariate analysis using the Cox regression model [5] .
Of the three factors that were investigated in both studies, the significant variable for survival was absence of further metastases (skeletal and visceral) [3, 5] . The interval between melanoma diagnosis and skeletal metastasis/MSCC diagnosis was only found to be significant in one of the studies [3] . Absence of visceral metastases remained significant on multivariate analysis using the Cox regression model [5] .
Variables found to be significant for survival on multivariate analysis in other studies but not in the included studies were female sex [10] , being ambulatory preradiotherapy [10] [11] [12] , being ambulatory postoperatively [10] , absence of further skeletal metastases [10, 12] , an interval of more than 15 months between cancer diagnosis and MSCC [10, 12] , an interval of more than 7 days between developing motor deficits and radiotherapy [8, [10] [11] [12] , an improvement in neurological status [10] and favourable histology [12, 13] . Many of these factors were identified in the included studies, but failed to reach significance on multivariate analysis. This may be because these factors are not as significant for MSCC secondary to melanoma as they are for MSCC secondary to other primaries. Alternatively, it may be that these factors would be found to be significant if the number of patients in the included studies had been higher.
Huttenlocher et al. [5] used the two variables that had remained significant on multivariate analysis, ECOG Performance Status of less than 2 and absence of visceral metastases, to develop a predictive scoring tool for survival. This tool could be used to determine which patients would receive maximum benefit from decompressive surgery; it could also be used in patients where surgery has been ruled out but radiotherapy has not to determine the optimum fractionation regime [5] . Further studies are needed to prospectively test the sensitivity of the tool.
Douglas et al. [11] produced a similar tool for MSCC secondary to cancer of unknown primary; the variables used were ECOG Performance Status of 1 or 2, absence of visceral metastases, being ambulatory before radiotherapy and an interval of more than 7 days between developing motor deficits and radiotherapy. This suggests that good ECOG Performance Status and absence
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of visceral metastases are relevant to MSCC patients with a variety of primaries, including melanoma. This is supported by the fact that both good ECOG Performance Status [8, 10] and absence of visceral metastases [10, 12] were found to be significant variables in other studies.
Huttenlocher et al. [5] also identified prognostic factors that affect functional outcome. The only factor shown to improve motor function was an interval of more than 7 days between developing motor deficits and radiotherapy. Factors shown to improve postoperative ambulatory status were ECOG Performance Status of 2 or less and being ambulatory before radiotherapy, with an interval of more than 7 days between developing motor deficits and radiotherapy showing a strong trend [5] . All of the patients with these three favourable factors were ambulatory after radiotherapy, suggesting that radiotherapy alone may be appropriate for these patients [5] .
Further studies are needed to prospectively validate this recommendation.
Freundt et al. [8] also looked at prognostic factors affecting functional outcome for patients with MSCC secondary to relatively radioresistant tumours; the only variable found to be significant on multivariate analysis was an interval of more than 15 months between cancer diagnosis and MSCC. This is interesting as melanoma was one of the relatively radioresistant tumours investigated by Freundt et al. [8] . This may be because this variable is not as significant for MSCC secondary to melanoma as it is for MSCC secondary to the other relatively radioresistant tumours investigated (renal cell carcinoma and colorectal cancer). Alternatively, it may be that these factors would be found to be significant if the number of patients in the included studies had been higher.
Neither of the included studies looked at prognostic factors affecting local control [3, 5] . Other studies that have looked at this found that significant variables included absence of visceral metastases and long-course radiotherapy (10 × 3 Gy, 15 × 2.5 Gy or 20 ×2 Gy) [12] . As only patients who have a good survival are likely to develop a recurrence of MSCC, it would make sense that long-course radiotherapy should be offered to patients with a good survival prognosis [12] . However, Freundt et al. [8] did not find any significant variables for local control. Further studies looking specifically at local control for melanoma patients are needed to prospectively identify whether there are any significant variables for this population.
Both included studies were retrospective cohorts, which raises the possibility that the results may be subject to hidden selection biases [3, 5] . Huttenlocher et al. [5] was the only paper identified that discussed prognostic factors for MSCC alone; Wedin et al. [3] also discuss other sites of skeletal metastasis. This means that the results are less specific for MSCC patients and so may be harder to generalize for this population. Furthermore, no p values were provided for many of the prognostic factors investigated by Wedin et al. [3] ; instead, differences between median survivals were given. It is therefore harder to draw meaningful conclusions from these. Univariate analysis using the χ 2 -test was carried out on the two variables for which P values were provided: perioperative lactate dehydrogenase and preoperative haemoglobin [3] . If these variables were shown to remain significant on multivariate analysis, they could potentially be incorporated into a prognostic scoring system.
The main strength of this review is that it is a comprehensive summary of the literature available on this topic. The main limitation of this review is that the total number of patients included across the included studies was only 39. In addition, the retrospective nature of the included studies creates the possibility of hidden selection biases affecting the results.
Conclusion
There is a paucity of studies looking specifically at MSCC secondary to melanoma. An ECOG Performance Status of 2 or less and absence of visceral metastases are associated independently with increased survival and have been incorporated into a predictive scoring tool that needs to be validated. Good functional outcome is associated with slow development of motor dysfunction, good performance status and being ambulatory before radiotherapy. Other factors that may affect survival, including perioperative lactate dehydrogenase level and preoperative haemoglobin level, may warrant further investigation.
